Most read articles by the same author(s)
- Sergio Iannazzo, A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen , Global and Regional Health Technology Assessment: Vol. 8 No. 1 (2021): January-December 2021
- Carlo Lucioni, Sergio Iannazzo, Silvio Mazzi, Giorgia Saporiti, Silvia Chiroli, Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy , Global and Regional Health Technology Assessment: Vol. 2 No. 1 (2015): January-April 2015
- Sergio Iannazzo, Aldo Pietro Maggioni, Edoardo Mannucci, Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Sergio Iannazzo, Chiara Distante, Angelo Guido Corsico, Costs of Tiotropium Bromide Delivered via the Respimat® Inhaler in COPD Patients in Italy , Global and Regional Health Technology Assessment: Vol. 3 No. 2 (2016): May-August 2016